HealthyNCT03484728
The Interaction Between Conditioned Pain Modulation and Expectation in Understanding the Placebo Effect of Pain Reduction
A study of Healthy, run by Rambam Health Care Campus at 1 site in Israel.
Trial summary
The interaction between conditioned pain modulation and expectation in understanding the placebo effect of pain reduction Read more about this study
- Who is it for?
- Ages 18 to 40 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 35 participants
- Where
- 1 siteIsrael
- Study dates
- 27 Mar 2018to 30 Jun 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy subjects
Who cannot join
- attention deficit.
- pain disorders.
Trial locations and contacts
1 site in 1 country.
About this study
The interaction between conditioned pain modulation and expectation in understanding the placebo effect of pain reduction
Read the detailed description
Conditioned pain modulation (CPM) has recently been coined for the psychophysical protocols that assess the functioning of descending pain inhibitory pathways in humans. There is a growing body of evidence points to the important role of spinal serotonin (5-HT) and noradrenaline (NA) in mediation of pain inhibition via CPM. On the other hand, there is also evidence on synergistic modulatory effect of the opioidergic control on CPM, however this issue is under debates. It seems therefore, that pre-treatment CPM assessment may be relevant for prediction of analgesic drug interaction and additive effects.
Placebo effects are inherent to every treatment and significantly contribute to clinical outcomes even in the presence of strong verum analgesic effects. From a psychological point of view, a series of recent studies supported the nature of the placebo effect as a learning phenomenon wherein verbally-induced expectations, cued and contextual conditioning or social learning are considered as the core mechanisms to produce a benefit. Placebo analgesic effects can be elicited by verbal instructions that generate anticipation for a benefit, thus creating expectations of analgesia. The effect of placebo is, primarily mediated by mu-receptors associated opioidergic neurotransmission. Alike brain structures activated by placebo manipulations, prefrontal cortex, cingulate cortex, PAG and RVM are the most important brain structures involved in initiating of opioid-mediated anti-nociception.
An interesting question that emerges is the extent of overlap between the serotono-noradrenergic analgesia represented by CPM, and opioidergic analgesia represented by expectation-based placebo manipulation, for pain reduction. It seems that the final pathway for the two systems is the descending analgesia tract(s). It is unclear, though, if such final common pathway dictates a limited analgesic effect, i.e., it can only be activated to a certain extent, regardless of which system activates it, and therefore additive effects of expectation and CPM are limited to a certain ceiling. Alternatively, different tracts of descending pain inhibition are activated by each system, and the analgesic effect is additive.
Cognitive cortical brain potentials (especially, a P300 waveform) evoked in response to a combination of rare and frequent innocuous sensory stimuli represent a neurophysiological tool for assessment attention. As this test bases on uncertainty and the expectation of upcoming stimuli, the recording of P300 may be relevant for evaluation cognitive processes associated with expectation-related placebo analgesia.
The main aim of this study is to explore the interaction between serotono-noradrenergic and opioidergic systems of analgesia in healthy subjects. More specifically, the investigator will study whether these two systems work in an additive or a complementary way, and whether the neurophysiological assessment of individual expectation capabilities can predict the placebo magnitude.
- Conditions
- Healthy
- Being tested
- placebo manipulation
- Keywords
- Conditional pain modulation, pain, placebo
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placebo manipulationBehavioural
application of nonactive body cream on forearm
| Study group | Role | What they receive |
|---|---|---|
| High-expectation placebo manipulation | Placebo comparator | application of nonactive body cream on forearm for 10 minutes Receives: Behavioral: placebo manipulation |
| Low-expectation placebo manipulation | Other | application of nonactive body cream on forearm for 10 minutes Receives: Behavioral: placebo manipulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in pain perception
pain units on a scale of 0-100. 0 no pain. 100 = the maximum pain
Measured: up to 2 weeks
Change in conditioned pain modulation (CPM)
change in pain units on a scale of 0-100. 0 no pain. 100 = the maximum pain
Measured: up to 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2018
- Study start27 Mar 2018
- Primary completion31 Dec 2019
- Study completion30 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- CPM was tested before and after the placebo manipulation (body cream application on forearm); based on the expectation of the cream analgesic response (high or low), two types of placebo manipulations were performed for each participant.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03484728
- Sponsor's protocol ID
- 574-17_RMB_CTIL
- Status last verified
- May 2021
- First submitted
- 31 Jan 2018
- Last updated
- 20 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Interaction Between Conditioned Pain Modulation and Expectation in Understanding the Placebo Effect of Pain Reduction
- ClinicalTrials.gov ID
- NCT03484728
- Acronym / sponsor ID
- 574-17_RMB_CTIL
- Conditions
- Healthy
- Keywords
- Conditional pain modulation, pain, placebo
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- 27 Mar 2018 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 30 Jun 2020 (actual)
- First posted
- 2 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The interaction between conditioned pain modulation and expectation in understanding the placebo effect of pain reduction
Detailed description
Conditioned pain modulation (CPM) has recently been coined for the psychophysical protocols that assess the functioning of descending pain inhibitory pathways in humans. There is a growing body of evidence points to the important role of spinal serotonin (5-HT) and noradrenaline (NA) in mediation of pain inhibition via CPM. On the other hand, there is also evidence on synergistic modulatory effect of the opioidergic control on CPM, however this issue is under debates. It seems therefore, that pre-treatment CPM assessment may be relevant for prediction of analgesic drug interaction and additive effects.
Placebo effects are inherent to every treatment and significantly contribute to clinical outcomes even in the presence of strong verum analgesic effects. From a psychological point of view, a series of recent studies supported the nature of the placebo effect as a learning phenomenon wherein verbally-induced expectations, cued and contextual conditioning or social learning are considered as the core mechanisms to produce a benefit. Placebo analgesic effects can be elicited by verbal instructions that generate anticipation for a benefit, thus creating expectations of analgesia. The effect of placebo is, primarily mediated by mu-receptors associated opioidergic neurotransmission. Alike brain structures activated by placebo manipulations, prefrontal cortex, cingulate cortex, PAG and RVM are the most important brain structures involved in initiating of opioid-mediated anti-nociception.
An interesting question that emerges is the extent of overlap between the serotono-noradrenergic analgesia represented by CPM, and opioidergic analgesia represented by expectation-based placebo manipulation, for pain reduction. It seems that the final pathway for the two systems is the descending analgesia tract(s). It is unclear, though, if such final common pathway dictates a limited analgesic effect, i.e., it can only be activated to a certain extent, regardless of which system activates it, and therefore additive effects of expectation and CPM are limited to a certain ceiling. Alternatively, different tracts of descending pain inhibition are activated by each system, and the analgesic effect is additive.
Cognitive cortical brain potentials (especially, a P300 waveform) evoked in response to a combination of rare and frequent innocuous sensory stimuli represent a neurophysiological tool for assessment attention. As this test bases on uncertainty and the expectation of upcoming stimuli, the recording of P300 may be relevant for evaluation cognitive processes associated with expectation-related placebo analgesia.
The main aim of this study is to explore the interaction between serotono-noradrenergic and opioidergic systems of analgesia in healthy subjects. More specifically, the investigator will study whether these two systems work in an additive or a complementary way, and whether the neurophysiological assessment of individual expectation capabilities can predict the placebo magnitude.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- CPM was tested before and after the placebo manipulation (body cream application on forearm); based on the expectation of the cream analgesic response (high or low), two types of placebo manipulations were performed for each participant.
| Arm | Type | Receives |
|---|---|---|
| High-expectation placebo manipulation | Placebo comparator | Behavioral: placebo manipulationapplication of nonactive body cream on forearm for 10 minutes |
| Low-expectation placebo manipulation | Other | Behavioral: placebo manipulationapplication of nonactive body cream on forearm for 10 minutes |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- healthy subjects
Key exclusion criteria (2 listed)
- attention deficit.
- pain disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placebo manipulationapplication of nonactive body cream on forearm | Behavioural | High-expectation placebo manipulation, Low-expectation placebo manipulation |
Primary outcome
Change in pain perception
Time frame: up to 2 weeks
pain units on a scale of 0-100. 0 no pain. 100 = the maximum pain
Change in conditioned pain modulation (CPM)
Time frame: up to 2 weeks
change in pain units on a scale of 0-100. 0 no pain. 100 = the maximum pain
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2021.
- Individual participant dataSharing planned: No
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Healthy, run by Rambam Health Care Campus at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in pain perception (time frame: up to 2 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2021.